Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Korean biotech company GI Innovation said Monday it has received Fast Track Designation from the US Food and Drug Administration for GI-102, its next-generation ...

The latest findings reported by Novartis reinforce Kesimpta’s efficacy in reducing annualised relapse rate (ARR). The ARTIOS trial evaluated the therapy in patients switching from oral ...

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies ...

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company announced FDA approval for KEYTRUDA QLEX injection, the first subcutaneous version ...

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

New Novartis data further support benefits of Kesimpta in relapsing MS following switch from oral disease modifying therapies: Basel Thursday, September 25, 2025, 15:00 Hrs [IST] ...

Medically reviewed by Femi Aremu, PharmD Key Takeaways While both contain semaglutide, Wegovy is approved specifically for weight management, whereas Ozempic is approved for the treatment of type 2 ...

Elicio’s AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis.

The FDA has approved Keytruda Qlex, a faster, under-the-skin cancer treatment offering convenience and flexibility. Here's what we know.